Illumina, a leader in genomics, reported its financial results for the third quarter of fiscal year 2024, revealing an adjusted earnings per share (EPS) of $1.14, surpassing the consensus estimate of $0.88. The company's total revenue reached $1.08 billion, slightly above the expected $1.08 billion, but reflecting a 3.49% decline year-over-year. The GAAP EPS was reported at $4.03. Illumina's adjusted net income for the quarter was $181 million, exceeding the estimate of $139.4 million. The company also adjusted its full-year guidance, raising its adjusted core EPS forecast to between $4.04 and $4.15, up from the previous range of $3.80 to $3.95. Despite the positive earnings report, Illumina's stock experienced a decline of 4% in post-market trading, attributed to mixed financial results and lowered revenue guidance for the fiscal year.